GTx Inc. Announces First Quarter 2005 Financial Results Conference Call and Webcast

, GTx, Inc.
Alan M.
She has published over 150 peer-reviewed manuscripts and has written two
books for women, The Healthy Woman and Our Health, Our Lives.

, loss of interest in usual pursuits), etc.

hormone condition

As people age, hormonal and metabolic changes lead to andropause and
sarcopenia. People gain an average of a pound of fat and lose half a pound of
muscle every year after the age of 30. Men may lose an average of 50% of
muscle between the ages of 30 and 90. You should
not place undue reliance on these forward-looking statements, which apply only
as of the date of this press release.

drops hormones

The symposium
will include Dr. He later completed his internship and residency at the
Boston Lying-In and Free Hospital for Women, which then became the Brigham and
Women's Hospital . There were no serious
dose-related or clinically significant adverse events observed in the clinical
trial. Diminished
muscle mass can cause frailty and loss of independence as well as worsen other
conditions such as osteoarthritis and osteoporosis.

diagnostic therapies

m. Symposium Will Feature Presentations by Dr .wsw.com/webcast/vivus/ and archived for 30 days. He
is well known for his ability to sift through even the most complex problems
in these areas and help guide women to the best kind of treatment if treatment
is necessary.
She now focuses her research and clinical practice on the consequences and
management of sex steroid depletion in women. Ostarine is being developed for
andropause, as well as other low testosterone conditions associated with
aging, such as sarcopenia.

Andropause is a medical condition of the mid-life man in which his testosterone drops significantly.

androgen testosterone

,
Eastern Time, on April 28 through May 5, 2005 and may be accessed by
dialing:
* 888-286-8010 from the United States and Canada or
* 617-801-6888 international
referencing reservation number 76732232. He is a
practicing gynecologist who specializes in peri and post-menopausal care,
problems with hormone replacement therapy and issues of mid-life sexuality.com.D. GTx's actual results and the
timing of events could differ materially from those anticipated in such
forward -looking statements as a result of these risks and uncertainties, which
include, without limitation , risks that GTx may not be able to commercialize
its product candidates if preclinical studies do not produce successful
results or clinical trials do not demonstrate safety and efficacy in humans;
if third parties do not manufacture the Company's product candidates in
sufficient quantities and at an acceptable cost, clinical development and
commercialization of its product candidates would be delayed; use of
third-party manufacturers may increase the risk that the Company will not have
adequate supplies of its product candidates; if third parties on whom the
Company relies do not perform as contractually required or expected, the
Company may not be able to obtain regulatory approval for or commercialize its
product candidates; the Company is dependent upon collaborative arrangements
to complete the development and commercialization of some of its product
candidates, and these collaborative arrangements may place the development of
its product candidates outside its control , may require it to relinquish
important rights or may otherwise be on terms unfavorable to the Company; and
if the Company is not able to obtain required regulatory approvals, the
Company will not be able to commercialize its product candidates.

onset consequences

Altman, Harvard Medical
School and Dr., VIVUS , Inc.
VIVUS will provide a live webcast of the symposium, accessible at
http://www.

Contact:
Carney Duntsch Jonathan M.

outlining hormone

MEMPHIS, Tenn.A.D
Investor and Media Relations Burns McClellan, Inc.

androgen exist

In its fourth
clinical program, GTx is developing its second SARM, ostarine, for andropause
and other chronic conditions related to aging, including sarcopenia.

VIVUS Announces Symposium/Web cast at the 53rd American College of Obstetricians and Gynecologists Annual Meeting

Sarcopenia is defined as the loss of muscle mass. Muscle provides strength and endurance ,
protects the skeletal system and helps maintain the immune system.S.

The condition is also called 'male menopause'.

outlining andropause

,
Eastern Time. Nugent
GTx, Inc.

hormones diagnostic

(Nasdaq: GTXI), a biopharmaceutical company dedicated to the discovery,
development and commercialization of therapeutics primarily related to the
treatment of serious men's health conditions and oncology, today announced
that it will host a conference call and webcast to discuss the Company's first
quarter 2005 financial results on Thursday, April 28, 2005 at 10:00 a.

About GTx
GTx is a biopharmaceutical company dedicated to the discovery, development
and commercialization of therapeutics primarily related to the treatment of
serious men's health conditions and oncology.P. The Phase I clinical trial
evaluated the safety, tolerability and pharmacokinetic profile of ostarine
using a single ascending dose, double -blind, placebo-controlled design in 96
healthy volunteers.
"We are encouraged by these safety data from our second SARM to enter
clinical trials," said Mitchell Steiner, M. This highlights the untapped potential of these novel drugs
for the treatment of many other men's health diseases, such as benign
prostatic hyperplasia (BPH), male infertility, male contraception, low libido
and anemia . In two of its clinical programs, the company
is developing ACAPODENE(R) (toremifene citrate) for two separate indications
in men: (1) a pivotal Phase III clinical trial for the prevention of prostate
cancer in high risk men and (2) a pivotal Phase III clinical trial for the
treatment of serious side effects of androgen deprivation therapy for advanced
prostate cancer.

discussed male

gtxinc. Dr. VIVUS' current product
pipeline includes four investigational products in late stage clinical
development.

GTx Inc.'s Second SARM Shows Phase I Clinical Safety

"
Ostarine is an oral nonsteroidal SARM that is designed to have positive
anabolic muscle and bone effects without affecting prostate growth and with
enhanced pharmacokinetic properties.

g.

consequences checklist

Davis's focusing on transdermal testosterone.

(Nasdaq: GTXI), a biopharmaceutical company dedicated to the discovery,
development and commercialization of therapeutics for serious men's health
conditions and oncology, today announced that it has completed a Phase I
clinical trial of ostarine, the Company's second selective androgen receptor
modulator (SARM) clinical product candidate.

About GTx
GTx is a biopharmaceutical company dedicated to the discovery, development
and commercialization of therapeutics primarily related to the treatment of
serious men's health conditions and oncology.

endocrinological condition

m.
GTx has a marketed product and four clinical programs., a subsidiary of Johnson + Johnson, are developing andarine, a
selective androgen receptor modulator (SARM), which they are planning to test
in Phase II clinical trials starting in the second half of 2005. In its fourth clinical program, GTx is developing its second SARM,
ostarine, for andropause which includes other chronic conditions related to
aging, including sarcopenia. GTx also has a marketed product, FARESTON(R)
(toremifene citrate 60mg) tablets, which is the same active compound as
ACAPODENE (R), for the treatment of metastatic breast cancer.
901-523-9700 212-213 -0006

discussed therapies

Additionally, you may access the live and subsequently archived webcast of
the conference call from the Investor Relations section of the Company's
website at http:/ /www. In
addition, GTx has an extensive preclinical pipeline generated from its own
discovery program which includes the specific product candidates, prostarine,
a SARM for benign prostatic hyperplasia (BPH), and andromustine, an anticancer
drug, for hormone refractory prostate cancer. Altman received his B.

Forward-Looking Information is Subject to Risk and Uncertainty
This press release contains forward-looking statements, including, without
limitation, statements related to GTx's current and anticipated clinical
trials and its other research and development programs. Forward-looking
statements involve risks and uncertainties.

g.

defines onset

The call and webcast will follow the release of the first
quarter 2005 financial results earlier that day. The marketed product
is FARESTON(R) (toremifene citrate 60mg) tablets for the treatment of
metastatic breast cancer. The company is developing the same active compound,
toremifene citrate, as ACAPODENE(R) in two of its clinical programs for men:
(1) a pivotal Phase III clinical trial for the prevention of prostate cancer
in high risk men and (2) a pivotal Phase III clinical trial for the treatment
of serious side effects of androgen deprivation therapy for advanced prostate
cancer. In its third clinical program, GTx and its partner , Ortho Biotech
Products, L. Susan R." The American College of Obstetricians and Gynecologists (ACOG )
has accredited this program to receive 1 continuing medical education (CME)
credit. He graduated with honors from the New York University School of
Medicine in 1975. Dr. Different compounds within the SARM class have demonstrated
in preclinical studies unique pharmacologic activities, with varying effects
on the prostate, spermatogenesis, muscle and bone growth, libido and red blood
cell production .
GTx has four clinical programs. These forward-looking
statements are based upon GTx's current expectations.

androgen defines

Dr. The annual report filed on Form 10-K
with the U.

pursuits male

To listen to the conference call, please dial:
* 800-638-5495 from the United States and Canada or
* 617-614-3946 international.com. on the "Transdermal Delivery of Hormones: The
Benefits of Non -Oral Estrogen Delivery and The Role of Testosterone Therapy
for Women. Altman's presentation addressing transdermal estrogen and Dr. in Biology at the University of
Pennsylvania. Davis is
President of the Australasian Menopause Society. For more information on clinical trials and products, please
visit the Company's web site at http://www.

CONTACT: Christina Weisgerber of VIVUS, Inc ., Vice Chairman and CEO of GTx.
"This allows us to continue to advance ostarine into additional clinical
trials. The total market potential for
andropause (sarcopenia) is in excess of $5 billion worldwide and will continue
to grow with a large aging population.P.

outcome consequences

Alan M.m. is a pioneer in the research and development of proprietary
products to restore sexual function for women and men., a subsidiary of Johnson + Johnson, are developing
andarine, a SARM, which is expected to enter a Phase II clinical trial in
2005.

male checklist

A playback of the call will be available from approximately 12:00 p.

This may result in other physical problems (e.

diagnostic consequences

GTx's drug discovery and
development programs are focused on small molecules that selectively modulate
the effects of estrogens and androgens, two essential classes of hormones. Results of the Phase I clinical trial indicated that
ostarine appears to be safe and was well tolerated. GTx's drug discovery and
development programs are focused on small molecules that selectively modulate
the effects of estrogens and androgens, two essential classes of hormones. GTx expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any such
statements are based.

significantly discussed

(Nasdaq: VVUS), a specialty pharmaceutical company focused on the research,
development and commercialization of products to restore sexual function in
women and men, today announced it will host a breakfast symposium on Monday,
May 9, 2005 at 6:00 a.
Susan R. MEMPHIS, Tenn ., GTx, Inc.

GTx's SARM Discovery Program
GTx believes that the ability to selectively target and modulate the
androgen receptor to maximize desired effects while minimizing unwanted
clinical effects will allow the development of many new drugs that are crucial
for men's health.

hormone condition

vivus. GTx plans to initiate a multiple ascending dose Phase I clinical trial
of ostarine in April 2005. About 17 million
Americans over the age of 75 have sarcopenia, and currently, there are no
approved treatment options available.

diagnostic menopause

The access code for the call is 66040231. Davis , MBBS, FRACP, PhD, is the Professor of Women's Health,
Monash University, and Director of the Monash University NHMRC Centre of
Clinical Research Excellence in Women's Health, Victoria, Australia. Davis
trained as a Specialist Physician in Endocrinology at Prince Henry's Hospital
in Melbourne and later completed her PhD on "The molecular biology of female
ovarian inhibin. In addition, GTx
has an extensive preclinical pipeline generated from its own discovery program
which includes the specific product candidates, prostarine, a SARM for benign
prostatic hyperplasia (BPH), and andromustine, an anticancer product
candidate, for hormone refractory prostate cancer.

endocrinological diagnostic

Davis, Monash University , Australia on the
Transdermal Delivery of Hormones

MOUNTAIN VIEW , Calif. He maintains his private practice in Brookline,
Massachusetts.

About VIVUS
VIVUS, Inc. In its third clinical program, GTx and its partner, Ortho
Biotech Products, L. Securities and Exchange Commission (the "SEC") on March 26, 2004
contains under the heading "Additional Factors That Might Affect Future
Results," a more comprehensive description of these and other risks to which
GTx is subject. Kathy Nugent, Ph.

low energy), psychological problems (e.

symptom checklist

Altman, MD is Assistant Clinical Professor of Obstetrics,
Gynecology and Reproductive Biology at Harvard Medical School." Her particular area of expertise is gynecological
endocrinology with an emphasis on clinical practice, research and education., +1-650-934-5240.

discussed outcome

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)